Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company’s lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Metrics to compare | GRTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGRTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.1x | −0.9x | −0.6x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price / Book | 0.0x | 1.1x | 2.6x | |
Price / LTM Sales | - | 171.9x | 3.1x | |
Upside (Analyst Target) | - | 281.5% | 51.3% | |
Fair Value Upside | Unlock | −0.3% | 7.3% | Unlock |